Home Newsfeeds Guggenheim Upgrades ServiceNow to Buy

Guggenheim Upgrades ServiceNow to Buy

Guggenheim analyst John Difucci upgrades ServiceNow (NYSE:NOW) from Neutral to Buy.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Guggenheim analyst John Difucci upgrades ServiceNow (NYSE:NOW) from Neutral to Buy.

Wall Street’s Most Accurate Analysts’ Views On 3 Materials Stocks Delivering High-Dividend Yields

By Avi Kapoor

May 15, 7:54 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often…

CMP

Demand Soars For Novo Nordisk’s Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition

By Benzinga Neuro

May 2, 5:48 AM

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.

CTLT

News

Globant And Formula 1 Announce Multi-Year Partnership To Elevate F1 Digital Experiences

By Benzinga Newsdesk

May 2, 8:36 AM

The first two projects of this collaboration will focus on improving the current pit wall system, a key source of information for racing teams, and enriching the fan experience mobile application used at each race

FWONK

Tigress Financial Initiates Coverage On Mobileye Global with Buy Rating, Announces Price Target of $44

By Benzinga Newsdesk

December 5, 1:49 PM

Tigress Financial analyst Ivan Feinseth initiates coverage on Mobileye Global (NASDAQ:MBLY) with a Buy rating and announces Price Target of $44.

MBLY

Guggenheim Upgrades ServiceNow to Buy

Related Posts

Wall Street’s Most Accurate Analysts’ Views On 3 Materials Stocks Delivering High-Dividend Yields

Demand Soars For Novo Nordisk’s Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition

Globant And Formula 1 Announce Multi-Year Partnership To Elevate F1 Digital Experiences

Tigress Financial Initiates Coverage On Mobileye Global with Buy Rating, Announces Price Target of $44